GVAX for Patients With Pancreatic Cancer
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma.
Clinical Pearls
Smitha Krishnamurthi, MD, associate professor of medicine, Case Western Reserve University, describes GVAX for patients with metastatic pancreatic adenocarcinoma. A phase II study of the vaccine waspresented at the 2014 Gastrointestinal Cancers Symposium.
- GVAX is a whole cell vaccine made of pancreatic cancer cells expressing GM-CSF. GVAX is given with low-dose cyclophosphamide.
- Patients in the study were randomized to receive cyclophosphamide/GVAX followed by CRS-207 or just cyclophosphamide/GVAX. CRS-207 is a modified Listeria bacteria which expresses mesothelin.
- Patients in the cyclophosphamide/GVAX and CRS-207 arm experienced an overall survival benefit of about 2 months (6.1 versus 3.9 months).
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
